Salarius Pharmaceuticals (SLRX) Stock Statistics & Valuation Metrics

Salarius Pharmaceuticals has a market cap or net worth of $3.37M. The enterprise value is $1.11M.

Salarius Pharmaceuticals has 1,051,782 shares outstanding. The number of shares has decreased by -2.65% in one year.

Salarius Pharmaceuticals’s return on equity (ROE) is -3.69 and return on invested capital (ROIC) is -330.78%.

The current PE Ratio of Salarius Pharmaceuticals is ―. Salarius Pharmaceuticals’s PEG ratio is >-0.00001.

In the last 12 months, Salarius Pharmaceuticals had revenue of 0.00 and earned -5.58M in profits. Earnings per share was -86.85.

In the last 12 months, operating cash flow was -4.43M and capital expenditures 4.00, giving a free cash flow of -4.43M billion.

Salarius Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Salarius Pharmaceuticals upcoming earnings date is Mar 30, 2026, Before Open (Confirmed).

Salarius Pharmaceuticals as a current ratio of 1.98, with Debt / Equity ratio of 0.00%

In the past 12 months, Salarius Pharmaceuticals has paid 0.00 in taxes.

Salarius Pharmaceuticals EV to EBITDA ratio is 0.08, with an EV/FCF ratio of 0.10.

Salarius Pharmaceuticals has $4.81M in cash and marketable securities with $0.00 in debt, giving a net cash position of $4.81M billion.

Gross margin is 0.02%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Salarius Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―